#United States #San Diego #Class Action #Robbins LLP #Inc. #LifeMD

Overview

Robbins LLP, a prominent firm specializing in shareholder rights litigation, has announced its role in a class action lawsuit against LifeMD, Inc. (NASDAQ: LFMD). The lawsuit encompasses individuals and entities that acquired securities of LifeMD from May 7, 2025, to August 5, 2025, during which the company is accused of spreading misleading information about its business performance and prospects.

Allegations Against LifeMD

The substantial claims outlined in the complaint reveal that LifeMD's executives allegedly over-inflated the company's competitive position in the virtual primary care market. According to the lawsuit, these executives failed to adequately address or disclose several critical factors affecting LifeMD's operations:
1. Overstated competitive advantages that potentially misled investors about the company’s market share and growth trajectory.
2. Reckless adjustments to LifeMD's 2025 financial guidance without accounting for rising customer acquisition costs, particularly stemming from its RexMD segment, which focuses on obesity-related medications such as Wegovy and Zepbound.
3. Overall, executives allegedly issued statements about LifeMD's business status that were unfounded and lacked reasonable support, leading investors to have a false sense of security regarding the company’s prospects.

Impact of the Allegations

The repercussions of LifeMD's misleading communications became apparent on August 5, 2025, when the company publicly acknowledged issues affecting its RexMD business segment. In a press release detailing its Q2 2025 results, LifeMD revised its full-year revenue and adjusted EBITDA guidance, citing "temporary challenges" that, while stated to be mostly resolved, still significantly impacted their growth expectations. This announcement precipitated a dramatic drop in LifeMD's stock price, plummeting $5.31 (44.8%), closing at $6.53 on the following trading day.

Next Steps for Investors

Investors who have experienced losses during this period may be eligible to join the class action. Those wishing to take a more active role can apply to serve as lead plaintiffs by filing documentation with the court by October 27, 2025. It is crucial for potential lead plaintiffs to act promptly, as they will represent the class members, guiding the litigation process. However, it is essential to note that participation in the class action is not a prerequisite for recovery; investors can remain absent class members if they choose.

Robbins LLP operates on a contingency fee basis, which means that shareholders bear no financial burden unless they recover their losses through the lawsuit.

About Robbins LLP

Since its inception in 2002, Robbins LLP has established itself as a leader in protecting shareholders’ rights, focusing on recovering losses, enhancing corporate governance, and holding executives accountable for misconduct. The firm not only champions investor rights but also serves as a resource for stakeholders to monitor corporate conduct and participate in restoration efforts following perceived wrongdoing.

Stay Informed

To stay updated on developments regarding the LifeMD class action, interested parties can sign up for Stock Watch alerts. These alerts not only inform investors about class action settlements but also keep them updated on corporate executives’ misdeeds which may affect shareholder value.

Contact Information:
For further inquiries or legal assistance, contact attorney Aaron Dumas, Jr. at Robbins LLP, or call (800) 350-6003.

Disclaimer: This article is for informational purposes only and does not constitute legal advice. Past outcomes do not guarantee similar results in future litigation.